Literature DB >> 23023708

Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Mary Jeanne Kreek1, Orna Levran, Brian Reed, Stefan D Schlussman, Yan Zhou, Eduardo R Butelman.   

Abstract

Addictive diseases, including addiction to heroin, prescription opioids, or cocaine, pose massive personal and public health costs. Addictions are chronic relapsing diseases of the brain caused by drug-induced direct effects and persisting neuroadaptations at the epigenetic, mRNA, neuropeptide, neurotransmitter, or protein levels. These neuroadaptations, which can be specific to drug type, and their resultant behaviors are modified by various internal and external environmental factors, including stress responsivity, addict mindset, and social setting. Specific gene variants, including variants encoding pharmacological target proteins or genes mediating neuroadaptations, also modify vulnerability at particular stages of addiction. Greater understanding of these interacting factors through laboratory-based and translational studies have the potential to optimize early interventions for the therapy of chronic addictive diseases and to reduce the burden of relapse. Here, we review the molecular neurobiology and genetics of opiate addiction, including heroin and prescription opioids, and cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023708      PMCID: PMC3534165          DOI: 10.1172/JCI60390

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  123 in total

1.  Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism.

Authors:  C Rivier; W Vale
Journal:  Brain Res       Date:  1987-10-06       Impact factor: 3.252

2.  Dopamine antagonist and "binge' cocaine effects on rat opioid and dopamine transporter mRNAs.

Authors:  R Spangler; Y Zhou; C E Maggos; A Zlobin; A Ho; M J Kreek
Journal:  Neuroreport       Date:  1996-09-02       Impact factor: 1.837

3.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

4.  Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain.

Authors:  J Turchan; W Lasoń; B Budziszewska; B Przewłocka
Journal:  Neuropeptides       Date:  1997-02       Impact factor: 3.286

5.  Regional mRNA expression of the endogenous opioid and dopaminergic systems in brains of C57BL/6J and 129P3/J mice: strain and heroin effects.

Authors:  S D Schlussman; J Cassin; Y Zhang; O Levran; A Ho; M J Kreek
Journal:  Pharmacol Biochem Behav       Date:  2011-07-23       Impact factor: 3.533

Review 6.  Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.

Authors:  Mary Jeanne Kreek; Gavin Bart; Charles Lilly; K Steven LaForge; David A Nielsen
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

7.  Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice.

Authors:  Yong Zhang; Roberto Picetti; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2008-09-10       Impact factor: 7.853

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans.

Authors:  M J Kreek; J Ragunath; S Plevy; D Hamer; B Schneider; N Hartman
Journal:  Neuropeptides       Date:  1984-12       Impact factor: 3.286

10.  Opioid mediation of cocaine-induced hyperactivity and reinforcement.

Authors:  A A Houdi; M T Bardo; G R Van Loon
Journal:  Brain Res       Date:  1989-09-11       Impact factor: 3.252

View more
  80 in total

1.  Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-08-12       Impact factor: 5.067

2.  Initial locomotor sensitivity to cocaine varies widely among inbred mouse strains.

Authors:  T Wiltshire; R B Ervin; H Duan; M A Bogue; W C Zamboni; S Cook; W Chung; F Zou; L M Tarantino
Journal:  Genes Brain Behav       Date:  2015-03       Impact factor: 3.449

3.  Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans.

Authors:  Orna Levran; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Ann Hum Genet       Date:  2015-02-27       Impact factor: 1.670

4.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

Review 5.  Emergence of sex differences in the development of substance use and abuse during adolescence.

Authors:  Cynthia Kuhn
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

6.  Drug addiction and stress-response genetic variability: association study in African Americans.

Authors:  Orna Levran; Matthew Randesi; Yi Li; John Rotrosen; Jurg Ott; Miriam Adelson; Mary Jeanne Kreek
Journal:  Ann Hum Genet       Date:  2014-04-26       Impact factor: 1.670

Review 7.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

8.  A Mixed-Method Analysis of Reports on 100 Cases of Improper Prescribing of Controlled Substances.

Authors:  James M DuBois; John T Chibnall; Emily E Anderson; Michelle Eggers; Kari Baldwin; Meghan Vasher
Journal:  J Drug Issues       Date:  2016-08-09

9.  Synaptic Plasticity and Signal Transduction Gene Polymorphisms and Vulnerability to Drug Addictions in Populations of European or African Ancestry.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  CNS Neurosci Ther       Date:  2015-09-19       Impact factor: 5.243

10.  Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex.

Authors:  V Echeverry-Alzate; E Giné; K M Bühler; J Calleja-Conde; P Olmos; M A Gorriti; R Nadal; F Rodríguez de Fonseca; J A López-Moreno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.